Literature DB >> 29622568

Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension.

Clara Hjalmarsson1,2, Göran Rådegran3,4, David Kylhammar5, Bengt Rundqvist1,2, Jonas Multing1,2, Magnus D Nisell6, Barbro Kjellström6.   

Abstract

Recent reports from worldwide pulmonary hypertension registries show a new demographic picture for patients with idiopathic pulmonary arterial hypertension (IPAH), with an increasing prevalence among the elderly.We aimed to investigate the effects of age and comorbidity on risk stratification and outcome of patients with incident IPAH.The study population (n=264) was categorised into four age groups: 18-45, 46-64, 65-74 and ≥75 years. Individual risk profiles were determined according to a risk assessment instrument, based on the European Society of Cardiology and the European Respiratory Society guidelines. The change in risk group from baseline to follow-up (median 5 months) and survival were compared across age groups. In the two youngest age groups, a significant number of patients improved (18-45 years, Z= -4.613, p<0.001; 46-64 years, Z= -2.125, p=0.034), but no significant improvement was found in the older patient groups. 5-year survival was highest in patients aged 18-45 years (88%), while the survival rates were 63%, 56% and 36% for patients in the groups 46-64, 65-74 and ≥75 years, respectively (p<0.001). Ischaemic heart disease and kidney dysfunction independently predicted survival.These findings highlight the importance of age and specific comorbidities as prognostic markers of outcome in addition to established risk assessment algorithms.
Copyright ©ERS 2018.

Entities:  

Mesh:

Year:  2018        PMID: 29622568     DOI: 10.1183/13993003.02310-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  27 in total

1.  Characteristics of Japanese elderly patients with pulmonary arterial hypertension.

Authors:  Yukiko Takahashi; Keiko Yamamoto; Nobuhiro Tanabe; Rika Suda; Ken Koshikawa; Yumiko Ikubo; Eiko Suzuki; Hiroki Shoji; Akira Naito; Hajime Kasai; Rintaro Nishimura; Takayuki Jujo Sanada; Toshihiko Sugiura; Ayako Shigeta; Seiichiro Sakao; Koichiro Tatsumi
Journal:  Pulm Circ       Date:  2020-10-27       Impact factor: 3.017

Review 2.  Endothelial Senescence: A New Age in Pulmonary Hypertension.

Authors:  Miranda K Culley; Stephen Y Chan
Journal:  Circ Res       Date:  2022-03-17       Impact factor: 17.367

3.  The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study.

Authors:  Stephan Rosenkranz; Richard Channick; Kelly M Chin; Bartosz Jenner; Sean Gaine; Nazzareno Galiè; Hossein-Ardeschir Ghofrani; Marius M Hoeper; Vallerie V McLaughlin; Camille Du Roure; Lewis J Rubin; Olivier Sitbon; Victor Tapson; Irene M Lang
Journal:  Eur J Heart Fail       Date:  2021-11-21       Impact factor: 17.349

4.  Retrospective observational analysis of hospital discharge database to characterize primary pulmonary hypertension and its outcomes in Spain from 2004 to 2015.

Authors:  Javier de-Miguel-Díez; Ana Lopez-de-Andres; Valentin Hernandez-Barrera; Isabel Jimenez-Trujillo; Manuel Mendez-Bailon; Jose M de Miguel-Yanes; Nuria Muñoz-Rivas; Martin Romero-Maroto; Rodrigo Jimenez-Garcia
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

5.  Sex-specific differences and survival in patients with idiopathic pulmonary arterial hypertension 2008-2016.

Authors:  Barbro Kjellström; Magnus Nisell; David Kylhammar; Sven-Erik Bartfay; Bodil Ivarsson; Göran Rådegran; Clara Hjalmarsson
Journal:  ERJ Open Res       Date:  2019-08-12

6.  Guideline implementation and early risk assessment in pulmonary arterial hypertension associated with congenital heart disease: A retrospective cohort study.

Authors:  Xiaoxian Deng; Bowen Jin; Shanshan Li; Yaping Li; Hongmei Zhou; Yang Wu; Menghuan Yan; Yuanping Hu; Qiu Qiu; Gangcheng Zhang; Xuan Zheng
Journal:  Clin Respir J       Date:  2019-08-29       Impact factor: 2.570

7.  Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up.

Authors:  Panagiota Xanthouli; Maria Koegler; Alberto M Marra; Nicola Benjamin; Lukas Fischer; Christina A Eichstaedt; Satenik Harutyunova; Christian Nagel; Ekkehard Grünig; Benjamin Egenlauf
Journal:  Respir Res       Date:  2020-05-24

Review 8.  Cardiac Magnetic Resonance Imaging in Pulmonary Arterial Hypertension: Ready for Clinical Practice and Guidelines?

Authors:  Barbro Kjellström; Anthony Lindholm; Ellen Ostenfeld
Journal:  Curr Heart Fail Rep       Date:  2020-10

9.  Dart to the target: an alternative bull's eye parametric display for European Society of Cardiology / European Respiratory Society goal-orientated risk reduction strategy in pulmonary arterial hypertension.

Authors:  Cihangir Kaymaz; Ozgur Yasar Akbal; Aykun Hakgor; Hacer Ceren Tokgoz; Seda Tanyeri
Journal:  Pulm Circ       Date:  2018-05-16       Impact factor: 3.017

10.  Biventricular diastolic dysfunction, thrombocytopenia, and red blood cell macrocytosis in experimental pulmonary arterial hypertension.

Authors:  Ji Young Lee; Karen A Fagan; Chun Zhou; Lynn Batten; Michael V Cohen; Troy Stevens
Journal:  Pulm Circ       Date:  2020-05-26       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.